Wang Zhongze, Cai Huarui, Zhao Erhu, Cui Hongjuan
State Key Laboratory of Silkworm Genome Biology, Medical Research Institute, Southwest University, Chongqing, China.
Engineering Research Center for Cancer Biomedical and Translational Medicine, Southwest University, Chongqing, China.
Front Cell Dev Biol. 2022 Feb 2;9:790129. doi: 10.3389/fcell.2021.790129. eCollection 2021.
Histone methylation status is an important process associated with cell growth, survival, differentiation and gene expression in human diseases. As a member of the KDM4 family, KDM4B specifically targets H1.4K26, H3K9, H3K36, and H4K20, which affects both histone methylation and gene expression. Therefore, KDM4B is often regarded as a key intermediate protein in cellular pathways that plays an important role in growth and development as well as organ differentiation. However, KDM4B is broadly defined as an oncoprotein that plays key roles in processes related to tumorigenesis, including cell proliferation, cell survival, metastasis and so on. In this review, we discuss the diverse roles of KDM4B in contributing to cancer progression and normal developmental processes. Furthermore, we focus on recent studies highlighting the oncogenic functions of KDM4B in various kinds of cancers, which may be a novel therapeutic target for cancer treatment. We also provide a relatively complete report of the progress of research related to KDM4B inhibitors and discuss their potential as therapeutic agents for overcoming cancer.
组蛋白甲基化状态是一个与人类疾病中的细胞生长、存活、分化及基因表达相关的重要过程。作为KDM4家族的一员，KDM4B特异性作用于H1.4K26、H3K9、H3K36和H4K20，这会影响组蛋白甲基化和基因表达。因此，KDM4B常被视为细胞通路中的关键中间蛋白，在生长发育以及器官分化中发挥重要作用。然而，KDM4B被广泛定义为一种癌蛋白，在包括细胞增殖、细胞存活、转移等与肿瘤发生相关的过程中起关键作用。在本综述中，我们讨论了KDM4B在促进癌症进展和正常发育过程中的多种作用。此外，我们重点关注了近期突出KDM4B在各类癌症中致癌功能的研究，这可能是癌症治疗的一个新的治疗靶点。我们还提供了一份关于KDM4B抑制剂研究进展的相对完整报告，并讨论了它们作为克服癌症的治疗药物的潜力。
